Increased concentrations of apo A-I and apo A-II fragments in the serum of patients with hepatocellular carcinoma by magnetic beads-assisted MALDI-TOF mass spectrometry

American Journal of Clinical Pathology

Volumn 141, Issue 1, 2014, Pages 52-61

  Liu, Yang ^a,d   Sogawa, Kazuyuki ^b   Sunaga, Masahiko ^b   Umemura, Hiroshi ^b   Satoh, Mamoru ^b   Kazami, Takahiro ^b   Yoshikawa, Masaharu ^a   Tomonaga, Takeshi ^b,c   Yokosuka, Osamu ^a   Nomura, Fumio ^b  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY HOSPITAL   (Japan)

^c NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^d BEIHUA UNIVERSITY   (China)

Author keywords

Apolipoprotein A I; Apolipoprotein A II; Hepatocellular carcinoma; MALDI TOF MS

Indexed keywords

ALPHA FETOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; DECARBOXYPROTHROMBIN; BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CATION EXCHANGE; CLINICAL FEATURE; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HEPATITIS C VIRUS; HUMAN; IMMUNOPRECIPITATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETER; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN PURIFICATION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; UPREGULATION; BLOOD; LIVER TUMOR; MAGNETISM; MALDI-TOF MS; MASS SPECTROMETRY; METHODOLOGY; VALIDATION STUDY; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; PROCEDURES;

APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; HEPATOCELLULAR CARCINOMA; MALDI-TOF MS;

APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; HUMANS; IMMUNOPRECIPITATION; LIVER CIRRHOSIS; LIVER NEOPLASMS; MAGNETICS; PEPTIDE FRAGMENTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; BIOMARKERS;

EID: 84894488319     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPBLFBNAP6N2UN     Document Type: Article

References (42)

1. Gomaa AI, Khan SA, Toledano MB, et al. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 2008;14:4300-4308.
2. Sangiovanni A, Ninno ED, Fasani P, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology. 2004;126:1005-1014. (Pubitemid 38451172)
3. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis. 2005;25:143-154. (Pubitemid 40781067)
4. Szklaruk J, Silverman PM, Charnsangavej C. Imaging in the diagnosis, staging, treatment, and surveillance of hepatocellular carcinoma. AJR Am J Roentgenol. 2003;180:441-454. (Pubitemid 36135030)
5. Nomura F, Ohnishi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels: analysis of 606 patients. Cancer. 1989;64:1700-1707. (Pubitemid 19251142)
6. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology. 1995;22:432-438.
7. Di Bisceglie AM, Hoofhagle JH. Elevations in serum alpha-fetoprotein levels in patients with chronic hepatitis B. Cancer. 1989;64:2117-2120. (Pubitemid 19280413)
8. Tsai SL, Huang GT, Yang PM, et al. Plasma des-γ-carboxyprothrombin in the early stage of hepatocellular carcinoma. Hepatology. 1990;11:481-488.
9. Nomura F, Ishijima M, Kuwa K, et al. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. Am J Gastroenterol. 1999;94:650-654. (Pubitemid 29124861)
10. Hakamada K, Kimura N, Miura T, et al. Des-gamma-carboxy prothrombin as an important prognostic indicator in patients with small hepatocellular carcinoma. World J Gastroenterol. 2008;14:1370-1377. (Pubitemid 351425216)
11. 2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res. 2004;64:2418-2423.
12. Cui R, He J, Zhang F, et al. Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGT) as hepatocellular carcinoma markers complementary to α-fetoprotein. Br J Cancer. 2003;88:1878-1882. (Pubitemid 36829662)
13. Ishizuka H, Nakayama T, Matsuoka S, et al. Prediction of the development of hepato-cellular-carcinoma in patients with liver cirrhosis by the serial determinations of serum alpha-L-fucosidase activity. Intern Med. 1999;38:927-931.
14. Jinno K, Tanimizu M, Hyodo I, et al. Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma. J Gastroenterol. 1998;33:376-382. (Pubitemid 28263653)
15. Song BC, Chung YH, Kim JA, et al. Transforming growth factor-β1 as a useful serologic marker of small hepatocellular carcinoma. Cancer. 2002;94:175-180. (Pubitemid 34049056)
16. Ding X, Yang LY, Huang GW, et al. Role of AFP mRNA expression in peripheral blood as a predictor for postsurgical recurrence of hepatocellular carcinoma: a systematic review and meta-analysis. World J Gastroenterol. 2005;11:2656-2661. (Pubitemid 40704287)
17. Miura N, Maeda Y, Kanbe T, et al. Serum human telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma. Clin Cancer Res. 2005;11:3205-3209. (Pubitemid 40627866)
18. Smith L, Lind MJ, Welham KJ, et al; for the Cancer Biology Proteomics Group. Cancer proteomics and its application to discovery of therapy response markers in human cancer. Cancer. 2006;107:232-241. (Pubitemid 44036551)
19. Diamond DL, Proll SC, Jacobs JM, et al. HepatoProteomics: applying proteomic technologies to the study of liver function and disease. Hepatology. 2006;44:299-308. (Pubitemid 44214867)
20. Feng JT, Shang S, Beretta L. Proteomics for the early detection and treatment of hepatocellular carcinoma. Oncogene. 2006;25:3810-3817. (Pubitemid 43980476)
21. Reymond MA, Schlegel W. Proteomics in cancer. Adv Clin Chem. 2007;44:103-142.
22. Nomura F, Tomonaga T, Sogawa K, et al. Application of proteomic technologies to discover and identify biomarkers for excessive alcohol consumption: a review. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;855:35-41. (Pubitemid 47082485)
23. Nomura F, Tomonaga T, Sogawa K, et al. Identification of novel and downregulated biomarkers for alcoholism by surface enhanced laser desorption/ionization-mass spectrometry. Proteomics. 2004;4:1187-1194. (Pubitemid 38445975)
24. Sogawa K, Itoga S, Tomonaga T, et al. Diagnostic values of surface-enhanced laser desorption/ionization technology for screening of habitual drinkers. Alcohol Clin Exp Res. 2007;31(suppl 1):S22-S26.
25. Poon TC, Yip TT, Chan AT, et al. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem. 2003;49:752-760. (Pubitemid 36513254)
26. Paradis V, Degos F, Dargère D, et al. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology. 2005;41:40-47. (Pubitemid 40066381)
27. Kanmura S, Uto H, Kusumoto K, et al. Early diagnostic potential for hepatocellular carcinoma using the SELDI ProteinChip system. Hepatology. 2007;45:948-956. (Pubitemid 46631563)
28. Cui JF, Liu YK, Zhou HJ, et al. Screening serum hepatocellular carcinoma-associated proteins by SELDI-based protein spectrum analysis. World J Gastroenterol. 2008;14:1257-1262.
29. Villanueva J, Philip J, Entenberg D, et al. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem. 2004;76:1560-1570. (Pubitemid 38338398)
30. Sawai S, Umemura H, Mori M, et al. Serum levels of complement C4 fragments correlate with disease activity in multiple sclerosis: proteomic analysis. J Neuroimmunol. 2010;218:112-115.
31. Sogawa K, Satoh M, Kodera Y, et al. A search for novel markers of alcohol abuse using magnetic beads and MALDI-TOF/TOF mass spectrometry. Proteomics Clin Appl. 2009;3:821-828.
32. Umemura H, Togawa A, Sogawa K, et al. Identification of a high molecular weight kininogen fragment as a marker for early gastric cancer by serum proteome analysis. J Gastroenterol. 2011;46:577-585.
33. Umemura H, Nezu M, Kodera Y, et al. Effects of the time intervals between venipuncture and serum preparation for serum peptidome analysis by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chim Acta. 2009;406:179-180.
34. Umemura H, Kodera Y, Nomura F. Effects of humidity on the dried-droplet sample preparation for MALDI-TOF MS peptide profiling. Clin Chim Acta. 2010;411:2109-2111.
35. Malik G, Ward MD, Gupta SK, et al. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin Cancer Res. 2005;11:1073-1085. (Pubitemid 40175756)
36. Chen G, Gharib TG, Huang CC, et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics. 2002;1:304-313.
37. Liang CR, Leow CK, Neo JC, et al. Proteome analysis of human hepatocellular carcinoma tissues by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics. 2005;5:2258-2271. (Pubitemid 40770587)
38. Kim J, Kim SH, Lee SU, et al. Proteome analysis of human liver tumor tissue by two-dimensional gel electrophoresis and matrix assisted laser desorption/ionization-mass spectrometry for identification of disease-related proteins. Electrophoresis. 2002;23:4142-4156. (Pubitemid 36131469)
39. Lee IN, Chen CH, Sheu JC, et al. Identification of human hepatocellular carcinoma-related biomarkers by two-dimensional difference gel electrophoresis and mass spectrometry. J Proteome Res. 2005;4:2062-2069. (Pubitemid 41814272)
40. Seimiya M, Tomonaga T, Matsushita K, et al. Identification of novel immunohistochemical tumor markers for primary hepatocellular carcinoma: clathrin heavy chain and formiminotransferase cyclodeaminase. Hepatology. 2008;48:519-530.
41. Cheng AJ, Chen LC, Chien KY, et al. Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clin Chem. 2005;51:2236-2244.
42. Steel LF, Shumpert D, Trotter M, et al. A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma. Proteomics. 2003;3:601-609. (Pubitemid 36570251)